{"id":"pregabalin-and-oxcarbazepine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Ataxia"},{"rate":null,"effect":"Hyponatremia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL1059","moleculeType":"Small molecule","molecularWeight":"159.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing calcium influx and decreasing the release of excitatory neurotransmitters. Oxcarbazepine blocks voltage-dependent sodium channels, stabilizing the inactive state of the channel and reducing repetitive neuronal firing. Together, these complementary mechanisms provide enhanced anticonvulsant and neuropathic pain relief effects.","oneSentence":"This combination product uses pregabalin to modulate calcium channels and reduce neurotransmitter release, while oxcarbazepine blocks sodium channels to stabilize neuronal membranes and reduce seizure activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:02:26.000Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy/seizure disorders"},{"name":"Neuropathic pain"},{"name":"Postherpetic neuralgia"}]},"trialDetails":[{"nctId":"NCT00855738","phase":"PHASE4","title":"A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-05","conditions":"Focal Epilepsy","enrollment":111},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02180880","phase":"PHASE4","title":"Symptom Based Treatment of Neuropathic Pain","status":"COMPLETED","sponsor":"Ju Seok Ryu","startDate":"2012-11","conditions":"Neuralgia, Spinal Cord Injury","enrollment":63},{"nctId":"NCT01390909","phase":"","title":"Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Epilepsy","enrollment":12386},{"nctId":"NCT00552526","phase":"PHASE4","title":"Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2007-11","conditions":"Epilepsy, Mental Retardation","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":224,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lyrica and Oxcarb"],"phase":"marketed","status":"active","brandName":"Pregabalin and Oxcarbazepine","genericName":"Pregabalin and Oxcarbazepine","companyName":"Ju Seok Ryu","companyId":"ju-seok-ryu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination product uses pregabalin to modulate calcium channels and reduce neurotransmitter release, while oxcarbazepine blocks sodium channels to stabilize neuronal membranes and reduce seizure activity. Used for Epilepsy/seizure disorders, Neuropathic pain, Postherpetic neuralgia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}